| Dedication: A Tribute to Dr. Setsuro Ebashi | |
| Preface | |
| Acknowledgements | |
| 1 | PPAR-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis | 3 |
| 2 | The Choice of an Appropriate Animal Species in the Study of Chlamydia pneumoniae as an Atherogenic Agent | 17 |
| 3 | Endothelial Cell Dysfunction - A Key Factor in Atherogenesis and its Reversal (Laboratory and Clinical Study) | 27 |
| 4 | Biochemical Mechanisms of Hyperhomocysteinemia in Atherosclerosis: Role of Chemokine Expression | 53 |
| 5 | Oxyradicals and Hypercholesterolemic Atherosclerosis | 63 |
| 6 | Identification, Regulation and Function of LOX-1, A Novel Receptor for Ox-LDL | 71 |
| 7 | Atherosclerosis and Angiotensin II in Hypercholesterolemia and Diabetes. A Role for AT[subscript 1] Receptors Beyond Hypertension | 83 |
| 8 | Basic and Clinical Results of New Statin: Pitavastatin | 99 |
| 9 | Reducing Cardiovascular Risk With HMG CoA Reductase Inhibitors, Potential Contribution From Platelets | 107 |
| 10 | Rapamycin-Sensitive Signal Transduction Pathways and the Control of Adipogenesis | 119 |
| 11 | Genetic Predisposition to Hypertension and Cardiovascular Disease | 131 |
| 12 | Role of Sympathetic Nervous System in Hypertension | 139 |
| 13 | Role of Hypothalamic Peptides in the Development of Hypertension | 155 |
| 14 | Myosin Light Chain Kinase in Endothelial Cell Calcium Signaling and Endothelial Functions | 163 |
| 15 | Sarpogrelate Inhibits Genes Involved in Vascular Neointimal Hyperplasia and Remodeling | 175 |
| 16 | A Nutritional Approach to Prevent High Blood Pressure | 187 |
| 17 | Cardiovascular and Renal Actions of Leptin | 197 |
| 18 | Brain Na, K-ATPase Enzymatic Activity and Cardiovascular Regulation | 211 |
| 19 | Development of Transdermal and Transbuccal Drug Delivery Systems for Cardioactive Drugs with Special Reference to Anti-Hypertensive Agents | 229 |
| 20 | Insulin Resistance and Experimental Hypertension | 247 |
| 21 | New Paradigm for Insulin Resistance: The HISS Story | 263 |
| 22 | Vanadium Effects in Diabetes | 277 |
| 23 | Dyslipoproteinemia and Fibrinolysis | 289 |
| 24 | Endothelins and Cardiovascular Disease in Diabetes | 301 |
| 25 | Usefulness of 5-HT[subscript 2A] Receptor Antagonists for the Treatment of Cardiovascular Complications in Diabetes | 317 |
| 26 | Selective Attenuation of Enhanced Angiotensin II Mediated Responses in the Streptozotocin Diabetic Rat Thoracic Aorta by Tempol | 327 |
| 27 | Role of Renin-Angiotensin System in Diabetic Heart Dysfunction and Changes in Phospholipase C Activity | 339 |
| 28 | Regulation of Cardiac Function in Diabetes | 353 |
| 29 | Diabetes and Cardiac Dysfunction | 373 |
| 30 | Mechanisms Underlying Contractile Dysfunction in Streptozotocin-Induced Type 1 and Type 2 Diabetic Cardiomyopathy | 387 |
| 31 | Protein Kinase C Signaling and Expression of the Diabetic Cardiac Phenotype | 409 |
| 32 | Oxidative Stress in Cardiovascular Complications of Diabetes | 427 |
| 33 | Augmented Energy Transfer in Rat Heart Mitochondria: Compensatory Response to Abnormal Household of Energy in Acute Diabetes | 439 |
| 34 | Ketosis, Tumor Necrosis Factor-[alpha] and Cardiovascular Disease in Type-1 Diabetic Patients | 455 |
| 35 | Epigenetic Alterations in Diabetic Cardiomyopathy | 465 |
| Index | 481 |
loading...